ArticleBritish journal of cancer2004
Mitoxantrone resistance in a small cell lung cancer cell line is associated with ABCA2 upregulation.
Article in British journal of cancer, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 67 citations in OpenAlex.
- Lysosomal Drug Sequestration Mediated by ABC Transporters and Drug Resistance.Pharmaceutics · 2025Article
- Global regulation via modulation of ribosome pausing by the ABC-F protein EttA.Nature communications · 2024Article
- The AKT inhibitor, MK-2206, attenuates ABCG2-mediated drug resistance in lung and colon cancer cells.Frontiers in pharmacology · 2023Article
- Anticancer and chemosensitization effects of cannabidiol in 2D and 3D cultures of TNBC: involvement of GADD45α, integrin-α5, -β5, -β1, and autophagy.Drug delivery and translational research · 2022Article
- ABC efflux transporters at blood-central nervous system barriers and their implications for treating spinal cord disorders.Neural regeneration research · 2020Review
- microRNAs targeting cellular cholesterol: implications for combating anticancer drug resistance.Genes & cancer · 2020Article
- Falling from grace: HPRT is not suitable as an endogenous control for cancer-related studies.Molecular & cellular oncology · 2019Article
- ATP-binding cassette transporter-2 (ABCA2) as a therapeutic target.Biochemical pharmacology · 2018Review
- Examination of Hypoxanthine Guanine Phosphoribosyltransferase as a biomarker for colorectal cancer patients.Molecular & cellular oncology · 2018Article
- The role of ATP-binding cassette transporter A2 in childhood acute lymphoblastic leukemia multidrug resistance.Iranian journal of pediatric hematology and oncology · 2014Review
- Ablation of the ATP-binding cassette transporter, Abca2 modifies response to estrogen-based therapies.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2012Article
- Article
- ABCA2 transporter deficiency reduces incidence of TRAMP prostate tumor metastasis and cellular chemotactic migration.Cancer letters · 2011Article
- ABC transporters: unvalidated therapeutic targets in cancer and the CNS.Anti-cancer agents in medicinal chemistry · 2010Review
- Identification of functional modules that correlate with phenotypic difference: the influence of network topology.Genome biology · 2010Article
- Molecular mechanisms of drug resistance in single-step and multi-step drug-selected cancer cells.Methods in molecular biology (Clifton, N.J.) · 2010Article
- The gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide.Current cancer drug targets · 2008Article
- Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies.Clinical pharmacology and therapeutics · 2008Review
- Article
- The ABCA subfamily--gene and protein structures, functions and associated hereditary diseases.Pflugers Archiv : European journal of physiology · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to find factors that could explain the accumulation difference of mitoxantrone in the BCRP1-negative GLC4-MITO cell line compared to GLC4. Comparative genomic hybridisation (CGH) was applied to determine chromosomal differences between GLC4 and GLC4-MITO. Comparative genomic hybridisation analysis revealed gain of 2q, 6p, 9q, 13q, 14q, 15q, 19q and Xp and loss of 1p, 2q, 3p, 3q, 4q, 6q, 8q, 11p, 16p, 17q, 18p, 20p and Xq. In the over-represented chromosomal areas, seven transporter genes were identified: ABCB6, ABCB2 (TAP1), ABCB3 (TAP2), ABCF1 (ABC50), ABCC10 (MRP7), ABCA2 (ABC2) and ABCC4 (MRP4). No RNA or protein upregulation was observed for ABCB6, ABCF1, ABCC10, ABCC4, ABCB2 and ABCB3, but an increased expression was detected for ABCA2 mRNA in GLC4-MITO. ABCA2 is known to be involved in resistance to estramustine. In the MTT assay, GLC4-MITO was two-fold resistant to estramustine compared to GLC4. Coincubation with estramustine and mitoxantrone increased mitoxantrone accumulation in GLC4-MITO, while this was not affected in GLC4. This suggests that estramustine is able to block mitoxantrone efflux in GLC4-MITO cells. These data reveal that cellular reduction of mitoxantrone in a mitoxantrone-resistant cell line is associated with overexpression of ABCA2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.